Please use this identifier to cite or link to this item: http://hdl.handle.net/1893/29828
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAdams, Alexandraen_UK
dc.date.accessioned2019-07-04T00:07:03Z-
dc.date.available2019-07-04T00:07:03Z-
dc.date.issued2019-07en_UK
dc.identifier.urihttp://hdl.handle.net/1893/29828-
dc.description.abstractIn 2014 the contribution of aquaculture to supply food for human consumption overtook wild-caught fish for the first time. Despite improvements in the aquaculture industry, it has been estimated that as much as 10% of all cultured aquatic animals are lost because of infectious diseases, amounting to >10 billion USD in losses annually on a global scale. Vaccination to prevent disease is used routinely in finfish aquaculture, especially for Atlantic salmon (Salmo salar), while in a limited capacity (or not at all) in many other fish species due to lack of vaccines, poor performance or cost. There has, nevertheless, been impressive progress in fish vaccine development over the last 4 decades with 24 licenced fish vaccines now commercially available for use in a variety of fish species. These comprise whole killed, peptide subunit, recombinant protein, DNA and live attenuated vaccines. Challenges do, however, still exist as the majority of commercial vaccines are killed whole cell pathogen preparations administered by intraperitoneal injection. This may not be the optimal route to deliver some vaccines, but lack of effective adjuvants and basic knowledge on immune response has hindered progress in the development of mucosal vaccines. The cost of injecting fish may also be prohibitive in some countries leading to disease treatment (e.g. with antibiotics) rather than using preventative measures. It is important that these issues are addressed as the industry continues to grow globally. Exciting opportunities exist for rapid development of fish vaccines in the future, with continued reduction in cost of technologies (e.g. of whole genome sequencing), regulations changing (e.g. DNA vaccines can now authorised in Europe), the introduction of novel antigen expression and delivery systems (such as virus-like particles, VLPs), development of novel adjuvants and advancements in the elucidation of basic mechanisms of mucosal immunity. Development of effective mucosal vaccines and optimisation of their delivery will facilitate novel vaccine development, and enable the aquaculture industries in LMIC to use vaccination routinely in the future. In addition, effective use of emergency (autogenous) vaccines will assist in tackling emerging disease challenges.en_UK
dc.language.isoenen_UK
dc.publisherElsevieren_UK
dc.relationAdams A (2019) Progress, Challenges And Opportunities In Fish Vaccine Development. Fish and Shellfish Immunology, 90, pp. 210-214. https://doi.org/10.1016/j.fsi.2019.04.066en_UK
dc.rightsThis item has been embargoed for a period. During the embargo please use the Request a Copy feature at the foot of the Repository record to request a copy directly from the author. You can only request a copy if you wish to use this work for your own research or private study. Accepted refereed manuscript of: Adams A (2019) Progress, Challenges And Opportunities In Fish Vaccine Development. Fish & Shellfish Immunology, 90, pp. 210-214. DOI: https://doi.org/10.1016/j.fsi.2019.04.066 © 2019, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/en_UK
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en_UK
dc.subjectFish vaccinesen_UK
dc.subjectFish health managementen_UK
dc.subjectVaccine administrationen_UK
dc.subjectVaccine developmenten_UK
dc.subjectMucosal vaccinesen_UK
dc.titleProgress, Challenges And Opportunities In Fish Vaccine Developmenten_UK
dc.typeJournal Articleen_UK
dc.rights.embargodate2020-04-28en_UK
dc.rights.embargoreason[Progress challenges and opportunities in fish vaccine developmentSA.pdf] Publisher requires embargo of 12 months after formal publication.en_UK
dc.identifier.doi10.1016/j.fsi.2019.04.066en_UK
dc.identifier.pmid31039441en_UK
dc.citation.jtitleFish and Shellfish Immunologyen_UK
dc.citation.issn1050-4648en_UK
dc.citation.volume90en_UK
dc.citation.spage210en_UK
dc.citation.epage214en_UK
dc.citation.publicationstatusPublisheden_UK
dc.citation.peerreviewedRefereeden_UK
dc.type.statusAM - Accepted Manuscripten_UK
dc.contributor.funderEuropean Commissionen_UK
dc.author.emailalexandra.adams@stir.ac.uken_UK
dc.citation.date27/04/2019en_UK
dc.contributor.affiliationInstitute of Aquacultureen_UK
dc.identifier.isiWOS:000471085000023en_UK
dc.identifier.scopusid2-s2.0-85065406711en_UK
dc.identifier.wtid1380286en_UK
dc.date.accepted2019-04-26en_UK
dcterms.dateAccepted2019-04-26en_UK
dc.date.filedepositdate2019-07-03en_UK
dc.relation.funderprojectTargeted disease prophylaxis in European fish farmingen_UK
dc.relation.funderref311993en_UK
rioxxterms.apcnot requireden_UK
rioxxterms.typeJournal Article/Reviewen_UK
rioxxterms.versionAMen_UK
local.rioxx.authorAdams, Alexandra|en_UK
local.rioxx.project311993|European Commission (Horizon 2020)|en_UK
local.rioxx.freetoreaddate2020-04-28en_UK
local.rioxx.licencehttp://www.rioxx.net/licenses/under-embargo-all-rights-reserved||2020-04-27en_UK
local.rioxx.licencehttp://creativecommons.org/licenses/by-nc-nd/4.0/|2020-04-28|en_UK
local.rioxx.filenameProgress challenges and opportunities in fish vaccine developmentSA.pdfen_UK
local.rioxx.filecount1en_UK
local.rioxx.source1050-4648en_UK
Appears in Collections:Aquaculture Journal Articles

Files in This Item:
File Description SizeFormat 
Progress challenges and opportunities in fish vaccine developmentSA.pdfFulltext - Accepted Version284.12 kBAdobe PDFView/Open


This item is protected by original copyright



A file in this item is licensed under a Creative Commons License Creative Commons

Items in the Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

The metadata of the records in the Repository are available under the CC0 public domain dedication: No Rights Reserved https://creativecommons.org/publicdomain/zero/1.0/

If you believe that any material held in STORRE infringes copyright, please contact library@stir.ac.uk providing details and we will remove the Work from public display in STORRE and investigate your claim.